Related Experiment Videos
[The so-called dihydralazine hepatitis. A contribution to the pathogenesis]
Deutsche Zeitschrift Fur Verdauungs- Und Stoffwechselkrankheiten
|January 1, 1985
Summary
Dihydralazine can cause liver injury, often presenting as perivenous necrosis. This drug-induced liver injury may be exacerbated by other hepatotoxic substances or pre-existing conditions.
Area of Science:
- Hepatology
- Toxicology
- Pharmacology
Background:
- Dihydralazine is a medication with known potential for causing liver injury.
- The pathogenesis of dihydralazine-induced liver injury is complex and may involve metabolic, toxic, and allergic mechanisms.
Purpose of the Study:
- To report and analyze liver injuries observed following dihydralazine administration.
- To investigate the role of co-administered drugs and pre-existing conditions in dihydralazine-induced liver injury.
Main Methods:
- Retrospective analysis of 14 patients with liver injury after dihydralazine use.
- Histopathological examination of liver biopsy samples.
- Review of patient medical history, including co-medications and co-exposures.
Main Results:
- Ten patients exhibited typical perivenous liver cell necrosis.
- Four patients showed mixed histological patterns, often associated with additional hepatotoxic exposures.
- Nine patients were treated with both dihydralazine and propranolol.
- One patient developed dihydralazine-like liver damage after propranolol alone.
- Two cases resulted in distinct liver fibrosis.
Conclusions:
- Dihydralazine can cause significant liver injury, characterized by perivenous necrosis.
- The risk and pattern of dihydralazine-induced liver injury may be influenced by co-administered drugs, particularly propranolol, and other hepatotoxic agents.
- The pathogenetic concept of dihydralazine-induced liver injury should incorporate the cumulative effects of multiple noxious agents.